Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review
- PMID: 22312502
- PMCID: PMC3263675
- DOI: 10.1155/2011/374012
Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review
Abstract
Individuals who carry an inherited mutation in the breast cancer 1 (BRCA1) and BRCA2 genes have a significant risk of developing breast and ovarian cancer over the course of their lifetime. As a result, there are important considerations for the clinician in the counseling, followup and management of mutation carriers. This review outlines salient aspects in the approach to patients at high risk of developing breast and ovarian cancer, including criteria for genetic testing, screening guidelines, surgical prophylaxis, and chemoprevention.
References
-
- van Riel E, Wárlám-Rodenhuis CC, Verhoef S, Rutgers E, Ausems M. BRCA testing of breast cancer patients: medical specialists’ referral patterns, knowledge and attitudes to genetic testing. European Journal of Cancer Care. 2010;19(3):369–376. - PubMed
-
- American Cancer Society. Breast cancer facts and figures 2009-2010. 2009.
-
- American Cancer Society. Cancer facts and figures. 2010.
-
- McClain MR, Palomaki GE, Nathanson KL, Haddow JE. Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications. Genetics in Medicine. 2005;7(1):28–33. - PubMed
-
- John EM, Miron A, Gong G, et al. Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. Journal of the American Medical Association. 2007;298(24):2869–2876. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
